NeuroNews

Even mild inflammation during pregnancy led mouse offspring to develop persistent brain overactivity, sensory sensitivity, repetitive behaviors, and increased seizure risk. Remarkably, one dose of…

The FDA granted Breakthrough Device Designation to NSE-FAST, the first rapid blood test to aid diagnosis of acute ischemic stroke (measuring neuron-specific enolase); a pivotal trial is planned for late 2026.

Newer oral drugs related to semaglutide medications such as Ozempic reduced pleasure-driven eating in mice by quieting a deep brain reward circuit. The finding could open new avenues for…

Scientists have identified a possible tipping point that helps determine whether Alzheimer’s-related brain changes lead to dementia. The key may lie in how the brain’s immune cells respond to…

A 12-week, placebo-controlled phase 2 trial found that an oral THC/CBD combination significantly reduced agitation in hospice-eligible patients with Alzheimer disease and other dementias, meeting…

A delay in following a patient’s right kidney mass was complicated by the patient’s refusal of a CT scan and the providers’ incomplete and conflicting documentation of patient education and…

The entire care team was faulted for poor fetal monitoring — an escalation and diagnostic-focus failure that ended in a fatal outcome, a lesson in shared responsibility.

Vermont became the first U.S. state to ban paraquat, one of the most-used herbicides, citing a possible link to Parkinson’s disease — as the EPA continues its safety review and the manufacturer phases out production.

CMS’s proposed CY2027 Medicare Physician Fee Schedule (July 14, 2026) modernizes physician payment and shifts toward value — with a projected ~1.2–1.7% conversion-factor cut; comments close Sept 14.